首页 › 基金 › Royalty Pharma Sub-Manager, LLC › CYTK
Royalty Pharma Sub-Manager, LLC 对 CYTK 的持仓历史
CYTOKINETICS INC · 医疗保健
Royalty Pharma Sub-Manager, LLC 在 Q3 2026 的 13F 申报中披露持有 CYTK(CYTOKINETICS INC)980,392 股,市值约 US$64.6M,约占其申报组合的 32.92%,在其申报持仓中市值排名第 1 位。 Royalty Pharma Sub-Manager, LLC 最近 4 个申报季度中有 4 个季度披露了 CYTK 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
Royalty Pharma Sub-Manager, LLC 对 CYTK 的持仓演变
Royalty Pharma Sub-Manager, LLC 于 Q4 2025 首次披露 CYTK 持仓:980,392 股(约 US$62.3M)。 该持仓在 Q2 2026 达到峰值 980,392 股,市值约 US$83.5M。 在 4 次申报中,Royalty Pharma Sub-Manager, LLC 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 980,392 股、市值约 US$64.6M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 980.39K | $62.29M | 新进 |
| Q1 2026 | 980.39K | $64.62M | 持有 |
| Q2 2026 | 980.39K | $83.52M | 持有 |
| Q3 2026 | 980.39K | $64.62M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CYTK 与 13F 数据
CYTK(CYTOKINETICS INC)属于医疗保健行业。我们追踪的基金中还有 42 只申报持有 CYTK,申报仓位最大的包括:T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CYTK 的基金
- T. Rowe Price Investment Management, Inc. 18.72M 股 · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 5.00M 股 · $425.95M · Q2 2026
- RTW INVESTMENTS, LP 2.86M 股 · $243.81M · Q2 2026
- Polar Capital Holdings Plc 2.25M 股 · $191.99M · Q2 2026
- Integral Health Asset Management, LLC 1.60M 股 · $136.30M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.20M 股 · $102.34M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.16M 股 · $98.81M · Q2 2026
- GW&K Investment Management, LLC 1.02M 股 · $67.08M · Q3 2026
- Melqart Asset Management (UK) Ltd 767.52K 股 · $65.39M · Q2 2026
- Foresite Capital Management IV, LLC 714.70K 股 · $60.88M · Q2 2026
- Deep Track Capital, LP 700.00K 股 · $59.63M · Q2 2026
- Affinity Asset Advisors, LLC 750.00K 股 · $49.43M · Q3 2026
更多关于 Royalty Pharma Sub-Manager, LLC
常见问题
How long has Royalty Pharma Sub-Manager, LLC held CYTK?
Royalty Pharma Sub-Manager, LLC has disclosed CYTK holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Royalty Pharma Sub-Manager, LLC's current position in CYTK?
As of Q3 2026, Royalty Pharma Sub-Manager, LLC holds 980.39K shares of CYTK (CYTOKINETICS INC), valued at $64.62M, representing 32.92% of its reported portfolio and ranking #1.
Has Royalty Pharma Sub-Manager, LLC been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Royalty Pharma Sub-Manager, LLC held unchanged its position in CYTK. The position peaked in Q2 2026 at 980.39K shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.